Personalized chemo dosing aims to beat tough testicular cancers

NCT ID NCT00864318

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a high-dose chemotherapy regimen called TICE in 101 patients with germ cell tumors that had relapsed or were not responding to standard treatment. The approach uses two cycles of paclitaxel and ifosfamide followed by three cycles of carboplatin and etoposide, with carboplatin doses adjusted for each patient to reduce side effects. The goal was to improve complete response rates while controlling toxicity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel, ifosfamide, carboplatin, and etoposide (chemotherapy drugs)
What this could lead to: If successful, this could offer a more effective treatment option for patients with hard-to-treat germ cell tumors, potentially improving survival rates.
What could go wrong: This is a phase 2 trial with a small number of participants, so results may not apply to everyone. High-dose chemotherapy carries serious risks like ear toxicity and kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor Neoplasms, Germ Cell and Embryonal Recurrence testis refractory cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMORS

Contacts and locations

Locations

CHU

Clermont-Ferrand, 63003, France
CHU

Strasbourg, 67091, France
Centre Antoine Lacassagne

Nice, 06050, France
Centre Léon Bérard

Lyon, 69373, France
Centre Paul Papin

Angers, 49933, France
Hopital St André

Bordeaux, 33075, France
Hopital TENON

Paris, 75970, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut Paoli Calmette

Marseille, 13273, France
Institut Val d'aurelle

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.